One of the most famous living biological scientists, Sir Ian Wilmut, just announced that he has Parkinson’s Disease. I wish him the best in dealing with this illness. Wilmut is very well-known for having cloned the first mammal, Dolly the Sheep. This work followed on the earlier breakthrough by Sir John Gurdon of cloning the […]
Ian Wilmut, who cloned Dolly, opens up about his Parkinson’s Disease Read More »
Australian stem cell biotech Mesoblast announced that it has received regenerative medicine advanced therapy (RMAT) designation from the U.S. FDA. This is very good news for the company and an encouraging development for the field. Interestingly, last month the FDA clarified that there is expanded RMAT designation that can include gene therapies too. At the Meeting
Mesoblast gets FDA RMAT; List of 10 total designations so far Read More »
Why can there be huge clinical trial fees for participants? I am often critical of for-profit stem cell clinics on this blog for numerous reasons. For instance, one thing that concerns me greatly about these clinics is that they charge patients to get experimental “treatments” that have not been proven to be safe or effective. But
Huge clinical trial fees allowed by FDA at times, details often secret Read More »
The transhumanism movement has been garnering attention lately for a variety of views including embracing aspects of heritable human genetic modification. Earlier this year I interviewed geneticist and transhumanist, George Church. In this post I interview molecular biophysicist and transhumanist Maria Konovalenko. She is the program coordinator at the Science for Life Extension Foundation. In
Interview with transhumanism leader Maria Konovalenko Read More »
CIRM has reinvented itself in a new form, CIRM 2.0, under the leadership of its new President Randy Mills. CIRM is almost like a stem cell that has changed into another new kind of stem cell. Us scientists could see the change coming in the “programming” at CIRM in terms of how it was operating as
CIRM 2.0 starts off with a bang Read More »
What is the “proper” amount of freedom of choice for patients in medicine? What if the treatments in question are experimental and come with their own baggage of associated risks, personal costs, and potential costs to society? More broadly, do patients have a fundamental right to medical choice? These questions seem particularly appropriate today on
Do Patients Have a Fundamental Right to Choice? Read More »
There was a time I used to watch Countdown with Keith Olbermann on a regular basis and for a few years, I really enjoyed it. After a while I kind of lost interest. Today Olbermann does a sports show on ESPN and it’s just not the same. He also seems like he’s not the same
Keith Olbermann, the Dr. Oz of Sports? Read More »
Change is in the air for the California stem cell agency, CIRM. It has a new President, Randy Mills, and CIRM is soon going to be like a new agency too. I recently did an interview with Mills that illuminates some of the big changes that are imminent. I also asked him what his favorite
Radical Vision for CIRM Future: Interview with New Prez Mills Read More »
An open letter to CIRM. By Jeanne Loring As the California Institute for Regenerative Medicine (CIRM) celebrates its successes on its 10th anniversary, there is coincidentally a less happy CIRM-related event. One of CIRM’s first investments in stem cell research was a network of dedicated stem cell laboratories throughout California. This program, called “shared labs”
Loring, et al. Open Letter to CIRM: Continue Shared Labs Read More »
I invited Nobel Laureate Shinya Yamanaka to do an interview on the future of clinical translation of induced pluripotent stem cells (iPSC). He provides some intriguing new insights into the iPSC field and the broader stem cell arena. PK: The Takahashi Team’s active Clinical Study using iPSCs to make RPEs to treat Macular Degeneration has
Shinya Yamanaka Interview on Clinical Use of IPSC Read More »